JAK1 and acquired polycythemia vera: Preventing and reducing STAT5 activation through the use of JAK2 inhibitors proved clinical efficacy in patients with myelofibrosis and PV [48, 49], and the first-in-class JAK1 and JAK2 inhibitor ruxolitinib was approved recently for selected categories of patients.